Cellectar Biosciences, Inc. Resources

News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • CLR 131
  • Clinical Trials
    • Overview
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Trial Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Trial Recruiting
    • Relapsed or Refractory Multiple Myeloma Clinical Trial Active, not recruiting
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

Sep 4, 2019

Cellectar Appoints Dov Elefant as Chief Financial Officer

Aug 15, 2019

CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study

Aug 14, 2019

Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

Aug 12, 2019

Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

Jul 9, 2019

Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

May 21, 2019

Cellectar Biosciences Announces Closing of $10.0 Million Financing

May 20, 2019

Cellectar Biosciences Announces $10.0 Million Financing

May 16, 2019

CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

May 15, 2019

Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

May 13, 2019
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...26
    © 2021 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A